Immunovant, Inc. (IMVT)

Immunovant Statistics

Total Valuation

Immunovant has a market cap or net worth of $2.56 billion. The enterprise value is $1.96 billion.

Market Cap	2.56B
Enterprise Value	1.96B

Important Dates

The last earnings date was Monday, August 11, 2025, before market open.

Earnings Date	Aug 11, 2025
Ex-Dividend Date	n/a

Share Statistics

Immunovant has 174.32 million shares outstanding. The number of shares has increased by 11.11% in one year.

Current Share Class	174.32M
Shares Outstanding	174.32M
Shares Change (YoY)	+11.11%
Shares Change (QoQ)	+2.48%
Owned by Insiders (%)	0.68%
Owned by Institutions (%)	49.83%
Float	66.98M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	4.13
P/TBV Ratio	4.21
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 12.32

Current Ratio	12.32
Quick Ratio	11.36
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -77.58% and return on invested capital (ROIC) is -51.06%.

Return on Equity (ROE)	-77.58%
Return on Assets (ROA)	-47.07%
Return on Invested Capital (ROIC)	-51.06%
Return on Capital Employed (ROCE)	-77.41%
Revenue Per Employee	n/a
Profits Per Employee	-$1.24M
Employee Count	362
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Immunovant has paid $1.73 million in taxes.

Income Tax	1.73M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -53.14% in the last 52 weeks. The beta is 0.66, so Immunovant's price volatility has been lower than the market average.

Beta (5Y)	0.66
52-Week Price Change	-53.14%
50-Day Moving Average	16.29
200-Day Moving Average	19.24
Relative Strength Index (RSI)	39.36
Average Volume (20 Days)	1,120,280

Short Selling Information

The latest short interest is 16.07 million, so 9.22% of the outstanding shares have been sold short.

Short Interest	16.07M
Short Previous Month	16.43M
Short % of Shares Out	9.22%
Short % of Float	23.99%
Short Ratio (days to cover)	12.33

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-471.10M
Pretax Income	-271.89M
Net Income	-447.30M
EBITDA	-470.69M
EBIT	-471.10M
Earnings Per Share (EPS)	-$2.84

Balance Sheet

The company has $598.91 million in cash and n/a in debt, giving a net cash position of $598.91 million or $3.44 per share.

Cash & Cash Equivalents	598.91M
Total Debt	n/a
Net Cash	598.91M
Net Cash Per Share	$3.44
Equity (Book Value)	608.54M
Book Value Per Share	3.56
Working Capital	598.86M

Cash Flow

In the last 12 months, operating cash flow was -$417.09 million and capital expenditures -$577,000, giving a free cash flow of -$417.66 million.

Operating Cash Flow	-417.09M
Capital Expenditures	-577,000
Free Cash Flow	-417.66M
FCF Per Share	-$2.40

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Immunovant does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.11%
Shareholder Yield	-11.11%
Earnings Yield	-17.47%
FCF Yield	-16.31%

Analyst Forecast

The average price target for Immunovant is $35.88, which is 144.25% higher than the current price. The consensus rating is "Buy".

Price Target	$35.88
Price Target Difference	144.25%
Analyst Consensus	Buy
Analyst Count	11
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1